<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00796055</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP177</org_study_id>
    <nct_id>NCT00796055</nct_id>
    <nct_alias>NCT00924235</nct_alias>
  </id_info>
  <brief_title>Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors</brief_title>
  <acronym>MEDI-547</acronym>
  <official_title>A Phase 1, Open-Label Study of MEDI-547 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biologic Activity of Intravenous Administration in Subjects With Relapsed or Refractory Solid Tumors Associated With EphA2 Expression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety, tolerability, and the highest dose of this drug given once every 3
      weeks or once every week, (per 21 day cycle) in adult subjects with relapsed or refractory
      solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine the safety, tolerability, and maximum tolerated dose (MTD) of MEDI 547 in a dose
      escalation cohort for either administration schedule 1 dose every 3 weeks or 1 dose every
      week in adult subjects with relapsed or refractory solid tumors.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    MI-CP177 study closed per sponsor decision.
  </why_stopped>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of MEDI-547 will be assessed based on the incidence of AEs, SAEs, laboratory abnormalities, physical examination changes, toxicities leading to permanent discontinuation of MEDI-547 and MEDI-547-related deaths.</measure>
    <time_frame>30 days after the last dose of MEDI-547.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The antitumor activity of MED-547 will be assessed based on objective response rate (ORR), time to response (TTR), duration of response (DR), time to progression (TTP), progression-free survival (PFS), and overall survival (OS).</measure>
    <time_frame>30 days after the last dose of MEDI-547</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MEDI-547</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-547</intervention_name>
    <description>Administered at a dose and schedule as determined by the subject's enrollment cohort as a 60 minute IV infusion as part of a 21-day treatment cycle.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For the dose-escalation cohort: cancer relapsed or refractory to at least 1 prior
             standard care systemic regimen standard therapy with previous histological
             confirmation of diagnosis of fallopian tube, primary peritoneal, endometrial,
             cervical, prostate, non-small cell lung, esophageal, gastric, bladder, and renal cell
             carcinomas or melanoma. Subjects with relapsed or refractory breast, epithelial
             ovarian, or colon cancer with previous histological confirmation of diagnosis must
             have progressed through more than 1 prior regimen of therapy. For patients enrolling
             at the NCI, pathology must be confirmed by the Department of Pathology, CCR, NCI.

          -  For the dose-expansion cohort: relapsed or refractory epithelial ovarian cancer with
             progression through more than 1 prior regimen of therapy, or relapsed or refractory
             fallopian tube, or primary peritoneal cancer with progression after at least 1 prior
             standard care systemic regimen, with previous histological confirmation of cancer
             diagnosis. For patients enrolling at the NCI, pathology must be confirmed by the
             Department of Pathology, Center for Cancer Research (CCR), NCI.

          -  Patients with the following histologic epithelial ovarian cancer cell types are
             eligible: Serous adenocarcinoma, endometrioid adenocarcinoma, mucinous adenocarcinoma,
             undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma,
             transitional cell carcinoma, malignant Brenner's Tumor, or adenocarcinoma not
             otherwise specified (NOS).

          -  For the dose-expansion cohort of subjects with relapsed or refractory ovarian cancer,
             subjects must have an archival tumor sample that demonstrates EphA2 expression by
             immunohistochemical stain.

          -  Males or females at least 18 years of age at the time of obtaining informed consent.

          -  Women of childbearing potential must have a negative serum pregnancy test within 72
             hours prior to MEDI-547 administration; and men and women of reproductive potential
             must agree to practice an effective method of avoiding pregnancy (this is not to
             include oral or implanted contraceptives (such as the &quot;pill&quot;, the &quot;patch&quot;, a Depo
             Provera shot, or hormone laced intrauterine device, but allows the following: non
             hormonal (copper), intrauterine device, female condom, diaphragm with spermicide,
             cervical cap, abstinence, use of a condom by the sexual partner or sterile sexual
             partner) beginning at the time the ICF is signed, and must agree to continue using
             such precautions while receiving MEDI-547 through 30 days after the last dose of
             MEDI-547.

          -  For the dose-escalation cohort: measurable disease by Response Evaluation Criteria in
             Solid Tumors (RECIST) criteria is desirable but not required. The following are not
             considered measurable: pleural effusion or ascites; osteoblastic/osteoclastic lesions
             or evidence of disease on bone scan alone; progressive irradiated lesions alone, bone
             marrow involvement, brain metastases, malignant hepatomegaly by physical exam alone;
             or chemical markers (eg, CA-125, carcinoembryonic antigen [CEA], or prostate specific
             antigen [PSA]). Recurrent disease following surgery or radiotherapy is measurable
             provided that 30 days have elapsed since treatment and that measurable disease exists
             outside the radiation port, or there is clear progression within the radiation port.

          -  For the dose-expansion cohort: measurable disease, by RECIST criteria is required. The
             following are not considered measurable: pleural effusion or ascites;
             osteoblastic/osteoclastic lesions or evidence of disease on bone scan alone;
             progressive irradiated lesions alone, bone marrow involvement, brain metastases,
             malignant hepatomegaly by physical exam alone; or chemical markers (eg, CA-125, CEA,
             or PSA). Recurrent disease following surgery or radiotherapy is measurable provided
             that 30 days has elapsed since treatment and that measurable disease exists outside
             the radiation port, or there is clear progression within the radiation port.

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.

          -  Life expectancy of greater than 16 weeks.

          -  For subjects who had prior treatment with chemotherapy, biological therapy,
             radiotherapy, or investigational therapy or had prior surgery: eligible for study
             entry if at least 30 days have passed since their treatment/surgery, provided that all
             toxicities related to prior treatment have resolved to ≤ Grade 1 severity by National
             Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (NCI CTCAE
             v3.0 and all surgical wounds have healed.

          -  Prior immunotherapy with approved agents (eg, trastuzumab, cetuximab, panitumumab,
             bevacizumab) is allowable if at least 30 days have passed.

          -  Absolute neutrophil count (ANC) ³ 1500/mm3, platelets ³ 100,000/mm3, hemoglobin &gt; 10.0
             g/dL, serum creatinine greater than or equal to 1.5 times the upper limit of normal
             [ULN] or calculated creatinine clearance &gt; 50 mL/min, serum bilirubin greater than or
             equal to 2 times the ULN, alkaline phosphatase &lt; 3 times the ULN, and aspartate
             transferase (AST) and alanine transferase (ALT) greater than or equal to 3 times the
             ULN.

          -  Prothrombin time (PT), partial thromboplastin time (PTT), and international normalized
             ratio (INR) that are within normal institutional limits.

          -  Written informed consent and Health Insurance Portability and Accountability Act
             (HIPAA) authorization (applies to covered entities in the USA only) obtained from the
             subject prior to receipt of any study medication or beginning study procedures.

        Exclusion Criteria:

          -  Pregnant or lactating women.

          -  A history of central nervous system metastases or primary central nervous system
             tumors.

          -  Symptomatic pleural effusion or ascites requiring paracentesis.

          -  Symptomatic peripheral neuropathy of Grade 2 or greater.

          -  Respiratory insufficiency requiring oxygen treatment, or lymphangitic involvement of
             lungs.

          -  Any evidence of hematemesis, melena, hematochezia, grade 2 or higher hemoptysis, or
             gross hematuria. Patients with grade 1 hemoptysis or microscopic hematuria will be
             permitted on study.

          -  Active or recent history (within 3 months) of keratitis or conjunctivitis.

          -  A history of significant adverse events related to a previously administered
             monoclonal antibody.

          -  A history of human immunodeficiency virus (HIV) or hepatitis virus infection
             (HBV,HCV)will be excluded to eliminate the risk of increased adverse events due to
             immune compromise or liver dysfunction.

          -  Any evidence or history of myocardial infarction, angina, or arrhythmia (including
             atrial fibrillation, multifocal premature ventricular contractions, ventricular
             bigeminy or trigeminy, ventricular tachycardia or requirement for anti-arrhythmics
             including digoxin), within 6 months prior to initiation of study drug.

          -  Any evidence of uncontrolled hypertension (systolic blood pressure &gt; 150 mm Hg) within
             3 months prior to initiation of investigational product.

          -  Subjects currently on anticoagulant therapy for thromboembolic disorders or
             prophylactic reasons will be excluded.

          -  Any evidence of severe congestive heart failure with severity New York Heart
             Association classification &gt; Class 1 within the past 12 weeks.

          -  A marked baseline prolongation of QTc interval (eg, demonstration of QTc interval ≥
             500 millisecs [ms]).

          -  A prior stroke or transient ischemic attack (TIA) within 6 months prior to initiation
             of (investigational product) MEDI-547.

          -  Any evidence of an active infection or systemic use of antimicrobials within 72 hours
             prior to initial treatment with MEDI-547.

          -  Current or planned participation (from the day of study entry through 30 days after
             the last dose of study drug) in a research protocol in which another investigational
             agent or therapy may be administered.

          -  Received another investigational agent within 30 days prior to initiation of study
             drug or not fully recovered from prior investigational treatment.

          -  A requirement for palliative chemotherapy, hormonal therapy, radiotherapy, surgery, or
             immunotherapy during the course of the study.

          -  For subjects in the dose-expansion cohort, history of prior malignancies within the
             past 5 years other than non-melanomatous skin cancers that have been controlled,
             carcinoma in situ of the cervix, or superficial bladder cancer.

          -  A general medical or psychological condition or behavior, including substance
             dependence or abuse that, in the opinion of the investigator, might not permit the
             subject to complete the study or sign the informed consent.

          -  Any condition that in the opinion of the investigator would interfere with evaluation
             of the investigational product or interpretation of study results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sherry Warwick</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2008</study_first_submitted>
  <study_first_submitted_qc>November 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2008</study_first_posted>
  <last_update_submitted>November 16, 2011</last_update_submitted>
  <last_update_submitted_qc>November 16, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 17, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

